Evidence map›Paper›PMID 32023969›Full record

ReviewMicroorganisms2020

Polyphenols in Alzheimer's Disease and in the Gut-Brain Axis.

V Prakash Reddy, Puspa Aryal, Sara Robinson, Raheemat Rafiu, Mark Obrenovich, George Perry

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microorganisms, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Pomegranate (Molecules (Basel, Switzerland) · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

V Prakash ReddyDepartment of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA.ORCID 0000-0003-3011-4175
Puspa AryalDepartment of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA.
Sara RobinsonDepartment of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA.ORCID 0000-0001-9849-6785
Raheemat RafiuDepartment of Chemistry, Missouri University of Science and Technology, Rolla, MO 65409, USA.
Mark ObrenovichDepartment of Veteran's Affairs Medical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, OH 44106, USA.
George PerryDepartment of Biology, University of Texas at San Antonio, San Antonio, TX 78249, USA.ORCID 0000-0002-6547-0172
Missouri University of Science and Technology · USLouis Stokes Cleveland VA Medical Center · USThe University of Texas at San Antonio · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polyphenolic antioxidants, including dietary plant lignans, modulate the gut-brain axis, which involves transformation of these polyphenolic compounds into physiologically active and neuroprotector compounds (called human lignans) through gut bacterial metabolism. These gut bacterial metabolites exert their neuroprotective effects in various neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), and also have protective effects against other diseases, such as cardiovascular diseases, cancer, and diabetes. For example, enterolactone and enterodiol, the therapeutically relevant polyphenols, are formed as the secondary gut bacterial metabolites of lignans, the non-flavonoid polyphenolic compounds found in plant-based foods. These compounds are also acetylcholinesterase inhibitors, and thereby have potential applications as therapeutics in AD and other neurological diseases. Polyphenols are also advanced glycation end product (AGE) inhibitors (antiglycating agents), and thereby exert neuroprotective effects in cases of AD. Thus, gut bacterial metabolism of lignans and other dietary polyphenolic compounds results in the formation of neuroprotective polyphenols-some of which have enhanced blood-brain barrier permeability. It is hypothesized that gut bacterial metabolism-derived polyphenols, when combined with the nanoparticle-based blood-brain barrier (BBB)-targeted drug delivery, may prove to be effective therapeutics for various neurological disorders, including traumatic brain injury (TBI), AD, and PD. This mini-review addresses the role of polyphenolic compounds in the gut-brain axis, focusing on AD.

Indexed as

AGEsAlzheimer’s diseaseantioxidantsenterolactoneflavonoidsglycationgut–brain axisneuroprotectionpolyphenolsreactive oxygen species

Identifiers

PMID32023969
PMCPMC7074796
OpenAlexW3004151941

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.